NovoCure Ltd. ((NVCR)) has held its Q4 earnings call. Read on for the main highlights of the call.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
NovoCure’s latest earnings call struck a cautiously optimistic tone, blending record revenue and growing patient adoption with persistent profitability challenges. Management emphasized clinical momentum, new product approvals, and a solid balance sheet, but also acknowledged gross margin pressure, rising R&D spend, and a slow ramp in newer indications that will weigh on near‑term earnings.
Record Revenue and Steady Year‑Over‑Year Growth
NovoCure reported full‑year net revenue of $655 million and fourth‑quarter revenue of $174 million, with both periods delivering 8% year‑over‑year growth. The performance underscores resilient demand for its tumor treating fields platform despite reimbursement friction and mixed macro conditions.
International Markets Drive Active Patient Expansion
Active patient growth was particularly strong outside the U.S., with Germany up 10%, France up 19%, and Japan up 29% year over year. U.S. active patients rose 4%, showing the domestic franchise is still expanding but at a slower pace than the company’s key international markets.
Optune Pax Wins Fast FDA Approval in Pancreatic Cancer
A major milestone came with the February 11 approval of Optune Pax for first‑line treatment of locally advanced pancreatic cancer in combination with nab‑paclitaxel and gemcitabine. The U.S. Food and Drug Administration completed its review at the 180‑day mark, quicker than the typical 9–12 month PMA timeline, and U.S. launch activities are now underway.
Rich Pipeline and Near‑Term Clinical Catalysts
NovoCure highlighted final data from two large randomized trials that have been published in leading medical journals and underpin PMA submissions in pancreatic cancer and brain metastases. Investors are watching for several top‑line readouts, including PANOVA‑4 next month, TRIDENT in the second quarter, and completion of KEYNOTE‑58 Phase III enrollment by year‑end.
Non‑GBM Franchise Shows Early but Growing Contributions
Non‑glioblastoma revenue is still modest but on an upward trajectory, with Optune Lua generating $10.4 million in 2025, including $5.8 million from NSCLC. Management expects non‑GBM products to contribute $15 million to $25 million in 2026, suggesting meaningful but incremental diversification away from the core GBM indication.
Balance Sheet Strengthened by Cash and Debt Reduction
The company ended the year with $448 million in cash and investments while repaying $561 million of convertible notes during the fourth quarter. With only $200 million drawn on its credit facility and no plans for additional borrowing, NovoCure believes it has sufficient runway to fund operations as new revenue streams ramp.
First Formal Guidance Maps Path Toward Profitability
For 2026, NovoCure issued its first formal outlook, calling for net revenue of $675 million to $705 million, or 3% to 8% growth at constant currency. The company is targeting adjusted EBITDA between negative $20 million and breakeven, signaling a clear intent to reach profitability on an adjusted basis next year.
Cost Discipline Emerging Across Operating Lines
Sales and marketing expenses were flat year over year at $240 million, reflecting discipline despite multiple launches and market expansions. General and administrative costs fell 6% to $178 million for the full year, with a sharp 41% drop in the fourth quarter tied mainly to lower share‑based compensation.
Losses Persist and Adjusted EBITDA Remains Negative
Despite revenue growth, NovoCure remains unprofitable, posting a fourth‑quarter net loss of $24 million, or $0.22 per share, and a full‑year net loss of $136 million, or $1.22 per share. Adjusted EBITDA was negative $16 million in the quarter and negative $34 million for the year, underscoring the work needed to reach sustainable earnings.
Gross Margin Compresses but Stabilizes in Mid‑70s
Gross margin declined to 76% in the fourth quarter and 75% for the full year, down from 79% and 77% in the prior year, pressured by lower prior‑period collections in the U.S. and higher costs such as tariffs. Management now expects gross margins to settle in the mid‑70% range in 2026, suggesting limited near‑term upside on this line.
R&D Investment Climbs as Late‑Stage Trials Advance
Research and development expense rose 19% in the fourth quarter to $61 million and 7% for the full year to $225 million. The increase reflects heavy investment in Phase III trials such as KEYNOTE‑58 and LUNAR‑2 as well as regulatory work needed to expand indications, positioning the pipeline for future revenue growth.
Optune Lua Launch Trails Expectations, Spend Reallocated
The initial launch of Optune Lua in the U.S. and Germany has been slower than expected, with only $10.4 million in 2025 revenue. Management said it has right‑sized marketing investment around Lua and is shifting capital toward indications and geographies with stronger near‑term return potential.
Reimbursement Lag to Slow Monetization of New Indications
NovoCure cautioned that Optune Pax revenue will trail active patient uptake as the company works through payer negotiations and coverage decisions. Management expects it could take one to two years to secure routine commercial coverage, making reimbursement progress a key risk factor for the growth ramp in pancreatic cancer.
Operational Hiccup Highlights Regulatory and Administrative Risk
The company disclosed that CMS temporarily halted its Medicare billing privileges during a DME supplier revalidation process. After NovoCure submitted a corrective action plan and passed reinspection, CMS rescinded the revocation and reinstated billing privileges retroactive to December 17, 2025, resolving the issue but spotlighting administrative risk.
Share‑Based Compensation to Pressure Near‑Term G&A
Management flagged that the first quarter will include another sizable G&A charge linked to share‑based compensation triggered by the Optune Pax approval. While non‑cash in nature, this expense will add noise to reported earnings and could obscure underlying operating trends over the near term.
New Market Launches to Contribute Gradually
NovoCure is expanding geographically with Optune Gio launches in Spain, Czechia, and British Columbia, alongside Optune Lua’s introduction in Japan. However, the company expects only modest revenue contributions from these new markets in 2026 as awareness builds and reimbursement pathways are established.
Guidance and Outlook Emphasize Gradual Growth and Margin Stability
Looking ahead to 2026, management guided to net revenue of $675 million to $705 million at constant FX, implying 3% to 8% growth driven by low‑ to mid‑single‑digit gains in Optune Gio and rising non‑GBM sales. The company targets adjusted EBITDA of negative $20 million to breakeven and anticipates gross margins in the mid‑70% range, while flagging a one to two year timeline for routine payer coverage in new indications.
NovoCure’s earnings call painted the picture of a company in transition, pairing record revenue and robust clinical momentum with continuing losses and reimbursement complexities. For investors, the story now hinges on execution: turning regulatory wins and a stronger balance sheet into durable revenue growth and delivering on the 2026 goal of reaching the brink of profitability.